PACB Surges 25% But Shorts Hold Their Ground Ahead of Q3

PACB heads into next week's Q3 earnings report with a 25% weekly gain behind it, a still-large short base in front of it, and options traders who are, by historical standards, the most bullish they have been all year.

The rally is striking in context. The stock closed at $2.45 on Tuesday, up 51% over the past month, reversing what had been a deeply negative year. Closely correlated peers moved in the same direction but with less force: DNA added 14% on the week, MRVI gained nearly 15%, and ILMN rose about 4%. PACB led the pack, which raises the immediate question of whether the move reflects something specific to the company or simply the genomics sector catching a bid ahead of the earnings season.

Short interest at 15.7% of free float is the most important tension in the setup right now. That is a large short position for a micro-cap life-science name, and it barely moved during the rally: shares short rose roughly 4% on the week, from around 45.9 million to 47.5 million. In other words, short sellers did not run. The borrow market is under no strain, with availability at about 304%, meaning there are three shares available to borrow for every two already shorted, and cost to borrow at just 0.51% is essentially free. The ORTEX short score of 61.97 reflects that combination: elevated short interest, but no squeeze mechanics in the lending pool. What that means in practice is that a continued rally would force short sellers to cover with their own conviction, not because the stock becomes unbearable to borrow.

Options positioning adds another layer. The put/call ratio has dropped to 0.06, the lowest reading of the past 52 weeks and nearly 1.5 standard deviations below its 20-day average of 0.08. That is a remarkably call-heavy book, consistent with traders positioning for further upside rather than hedging against a reversal. A year ago the PCR ran as high as 0.20; the current level suggests the options market has tilted decisively bullish into the print.

The Street, by contrast, has not caught up. The mean analyst price target was $2.54 as of late October, barely above where the stock already trades. The most recent formal action came in September, when UBS assumed coverage with a Neutral rating and a $1.35 target, well below the current price. Barclays carries an Underweight with a $1.50 target. The only Overweight on the register is Stephens, with a $2.00 target from last November. Taken together, the analyst community's targets were set when the stock was trading below $2, and none have been revised to reflect the recent move. That leaves the street consensus effectively a negative signal relative to current levels, even though the ratings themselves are mixed.

The fundamental debate is well worn. Bulls point to improving gross margins, Revio platform utilisation at its highest since launch, and management's guidance for sequential Vega placements through 2026. Bears note that gross margins are forecast to decline from the 40.4% reported last quarter, instrument demand remains softer than expected, and China remains a headwind. The Benzinga bear case also references 2023 and 2024 China demand concerns, suggesting these materials have not been refreshed for the current cycle. The earnings history does not favour optimism: the last two quarterly reports each produced an immediate one-day decline of around 9% and 19% respectively, with five-day losses even larger. Q3 results are due November 4.

On the ownership side, BlackRock added over 7 million shares in the quarter ending September, bringing its stake to 10.4% of shares. ARK Investment Management remains the second-largest holder at 9.6%, adding about 1.3 million shares in the same period. Both positions are freshly reported. No 13D activist is on the register; all large-holder filings are passive 13G schedules, with stakes as last disclosed and subject to change without further filing if holders drop below the 5% threshold.

With Q3 results a week away, the tension is between a technically and sentiment-driven rally, a short base that has not flinched, and a history of sharp post-earnings declines. Whether the large short position and call-heavy options book create amplified moves in either direction after the print is the question worth watching.